RHBC
VRTX icon

R.H. Bluestein & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

R.H. Bluestein & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,251
Closed -$252K – 448
2021
Q2 		$252K Hold
1,251
– – 0.01% 365
2021
Q1 		$269K Sell
1,251
-500
-29% -$110K 0.01% 339
2020
Q4 		$414K Buy
1,751
+500
+40% +$115K 0.02% 221
2020
Q3 		$340K Sell
1,251
-1,200
-49% -$331K 0.02% 221
2020
Q2 		$712K Buy
2,451
+1,100
+81% +$298K 0.04% 114
2020
Q1 		$321K Buy
1,351
+200
+17% +$45.9K 0.03% 171
2019
Q4 		$252K Buy
+1,151
New +$233K 0.01% 302

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

R.H. Bluestein & Co's VRTX Position: Q3 2021 in Review

R.H. Bluestein & Co sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 1,251 shares — an estimated $252K sold.

R.H. Bluestein & Co first reported a position in VRTX in Q4 2019 and held it in 7 quarters. The position peaked at $712K in Q2 2020. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • R.H. Bluestein & Co reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • R.H. Bluestein & Co sold 1,251 Vertex Pharmaceuticals shares in Q3 2021, an estimated $252K.
  • R.H. Bluestein & Co first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • R.H. Bluestein & Co's Vertex Pharmaceuticals position peaked at $712K in Q2 2020.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on R.H. Bluestein & Co's 13F filing for Q3 2021, filed 12 Nov 2021.